Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 75%
filed 2026-06-18
Item 3.02
The filing discloses Item 3.02 (Unregistered Sales of Equity Securities) with a cross-reference to Item 8.01 for substantive details. Item 3.02 is the dedicated disclosure item for dilutive equity issuances such as private placements and PIPEs. While the actual transaction details are incorporated by reference to Item 8.01 (not shown in this excerpt), the presence of Item 3.02 itself signals an unregistered equity sale, which is material to investors as it affects share dilution and capital structure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 3.03
The Board approved a 4-to-1 reverse stock split effective June 23, 2026, undertaken to satisfy Nasdaq's $1.00 minimum bid price requirement for continued listing. The reverse split modifies shareholder rights by reducing share count and changing the trading symbol and CUSIP.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
Item 1.01
IIOT-OXYS entered into Amendment No. 1 to a Securities Purchase Agreement on June 12, 2026, authorizing issuance of up to 167 shares of Series D Convertible Preferred Stock, with a Third Additional Closing on June 16, 2026 issuing 30 shares (27 purchased + 3 as equity incentive) to accredited investor GHS under Section 4(a)(2) and Regulation D Rule 506(b). This unregistered private placement of preferred stock materially dilutes existing shareholders and affects the registrant's capital structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-18
Item 5.01
The disclosure describes a transfer of 61 shares of Series A Preferred Stock from Kelly Kirchhoff to Jeff Foster on June 15, 2026, which resulted in a shift of voting control of the Company from Kirchhoff to Foster. The filing explicitly states that "voting control of the Company shifted from Mr. Kirchhoff to Mr. Foster" and that Series A Preferred Stock ownership "provides the holders with voting rights sufficient to control matters submitted to shareholders." This constitutes a material change of control event under Item 5.01, even though no officers or directors formally changed positions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-06-18
Item 1.01
Tianci International consummated a registered public offering of 6,055,000 units (4,055,000 standard units and 2,000,000 pre-funded units) at $0.81 per unit on June 17, 2026, generating approximately $4.9 million in gross proceeds. Each unit includes common stock (or pre-funded warrant) and common warrants with anti-dilution provisions, materially diluting existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
Item 8.01
The filing discloses an At Market Issuance Sales Agreement (ATM) under which Sonoma Pharmaceuticals may offer and sell shares of common stock through an agent. The company has already sold 173,073 shares for $574,633 and increased the aggregate offering price to $3,641,703 as of the filing date. ATM offerings are classic dilutive equity issuances that signal capital-raising activity and potential shareholder dilution, material to investors assessing ownership stakes and capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
Lifeway Foods held its 2026 Annual Meeting of Shareholders on June 17, 2026, with voting results on four proposals: election of seven directors (Kirk Chartier, Juan Carlos Dalto, Rachel Drori, Andee Harris, Susie Hultquist, Dorri McWhorter, and Julie Smolyansky), ratification of Grant Thornton LLP as independent auditors, advisory approval of executive compensation, and election of Jason Scher. Detailed vote tallies for each proposal are disclosed.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
Carlyle Credit Solutions completed an unregistered sale of 322,258 shares of Class I common stock for $5.9 million under Section 4(a)(2) and Regulation D exemptions, increasing outstanding shares from approximately 95.1 million to 95.4 million and materially affecting shareholder ownership and capital structure.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-18
Item 7.01
The Board declared a quarterly dividend of $0.14 per share on Class I Common Stock, payable July 29, 2026, which is material to shareholders as it affects distributions and total return.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-18
Item 8.01
The Company disclosed its net asset value per share of $18.20 for Class I Common Stock as of May 31, 2026 and aggregate NAV of $1.7 billion as of June 17, 2026, along with a status update on its continuous private offering of unregistered shares totaling $2.5 billion in cumulative consideration.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 7.01
Alpha Metallurgical Resources disclosed significant damage to a critical stacker reclaimer machine at Dominion Terminal Associates (65% owned) caused by high winds on June 14, 2026, rendering the equipment inoperable and forcing the company to issue force majeure notices to customers and seek alternative shipping capacity.
View raw filing on EDGAR →
8-K
M&A activity
confidence 94%
filed 2026-06-18
Item 1.01
Denali entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in gross proceeds. The transaction is subject to customary closing conditions including Hart-Scott-Rodino review, and the company intends to use proceeds to fund its clinical pipeline.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from Adicet Bio's June 17, 2026 Annual Meeting of Stockholders. The filing reports final voting tallies for three proposals: election of Class II directors (Chodakewitz, Dubin, Grissinger), non-binding advisory vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor. All three proposals passed with substantial majorities, making this a routine but material governance disclosure that affects investor understanding of board composition and audit oversight.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear disclosure of shareholder voting results from Zentalis Pharmaceuticals' June 16, 2026 Annual Meeting of Stockholders. The filing reports the outcomes of three proposals: election of two Class III directors (David Johnson and Jan Skvarka, Ph.D.), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three items passed. This is a routine but material disclosure required under Item 5.07 of Form 8-K.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-18
Item 1.01
CoreWeave completed a material debt offering of $1,250 million USD Notes and €2,000 million EUR Notes on June 18, 2026, pursuant to definitive indenture agreements. The offering includes detailed covenant restrictions, change-of-control provisions, and use of proceeds for debt repayment, constituting a material capital structure event.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 8.01
CMS recalculated the Company's Medicare Advantage Star Ratings upward for two contracts (H5141 from 3.5 to 4.5 Stars, H8010 from 4.0 to 4.5 Stars) following a court judgment in Clover Insurance Co. v. HHS. These rating improvements directly impact Quality Bonus Payments for payment year 2027, which are material to a Medicare Advantage insurer's revenue and competitive position. While this is favorable news, it does not fit neatly into the more specific event categories (it is neither an impairment, litigation settlement, nor operational change), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear disclosure of shareholder vote results from Nautilus Biotechnology's June 17, 2026 annual meeting, covering four matters: election of Class II directors (Parag Mallick and Farzad Nazem), ratification of PricewaterhouseCoopers LLP as independent auditor, advisory vote on executive compensation, and advisory vote on frequency of future Say on Pay votes. The filing presents detailed voting tallies for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear disclosure of shareholder voting results from GoodRx's Annual Meeting of Stockholders held on June 16, 2026. The filing reports final vote tallies for three proposals: election of three Class III directors (Wendy Barnes, Ronald E. Bruehlman, and Gregory Mondre), ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. The disclosure includes vote counts (FOR, AGAINST, WITHHELD, ABSTAINED) and broker non-votes for each proposal, with all three proposals passing. This is a quintessential Item 5.07 shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This 8-K Item 5.07 discloses the final voting results from Rackspace Technology's June 18, 2026 annual meeting of stockholders, including four proposals: election of two Class III directors (Gajen Kandiah and Michael Weston), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2020 Equity Incentive Plan. All proposals passed with substantial majorities. This is a routine but material shareholder vote results disclosure required by Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear disclosure of shareholder vote results from SoFi's June 17, 2026 annual meeting of stockholders. The filing reports voting outcomes on three proposals: election of ten directors, non-binding advisory vote on executive compensation, and ratification of Deloitte & Touche LLP as independent auditor. All three proposals passed with substantial majorities. This is a routine but material Item 5.07 disclosure required by SEC rules following stockholder meetings.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-18
Item 5.02
Rich Hossfeld resigned from the Board and Audit Committee effective June 12, 2026. The principal disclosed action is a director's departure. While the filing also mentions Raffi Garabedian replacing him on the Audit Committee, the core event is Hossfeld's resignation. The company explicitly states the resignation was not due to disagreement, and board composition changes are material to investors assessing governance and oversight.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-18
Item 8.01
The filing discloses preliminary court approval of a settlement in shareholder derivative litigation (Yingling v. Cannito, et al.) involving breach of fiduciary duty and securities law violations against individual defendants. The settlement requires Redwire to adopt comprehensive corporate governance reforms and pay attorneys' fees funded by insurance. This is a material litigation settlement that affects the company's governance structure and obligations, with a final approval hearing scheduled for July 30, 2026.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 8.01
GRI Bio announced FDA Orphan Drug Designation (ODD) for GRI-0621 in idiopathic pulmonary fibrosis, a significant regulatory milestone that provides potential seven-year U.S. market exclusivity, tax credits, and enhanced FDA engagement. While this is a material regulatory achievement for a clinical-stage biotech company, it does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M&A activity, impairment, or litigation). The ODD is a positive regulatory catalyst that would affect investor assessment of the company's development pathway and long-term value creation.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-18
EX-99.1
K Wave Media received a written notification from Nasdaq dated June 16, 2026, stating the Company is not in compliance with the minimum $15,000,000 Market Value of Publicly Held Shares (MVPHS) requirement for continued listing on The Nasdaq Global Market. The Company has a 180-calendar-day compliance period to restore compliance, or face delisting. This is a clear notice of failure to satisfy a continued listing rule under Item 3.01 of the 8-K taxonomy.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 7.01
The disclosure announces that the Department of Health – Abu Dhabi has granted Investigational New Drug (IND) status for NEO212, marking the first international regulatory clearance for the Company's lead clinical-stage drug candidate following Phase 1 completion. This represents a material regulatory milestone that advances the development pathway and expands the Company's clinical footprint internationally. While not a traditional earnings release, exec change, M&A activity, or other specifically enumerated event type, this regulatory approval is material to investors assessing the Company's clinical development progress and commercial prospects for a key asset.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-18
The filing's primary disclosure under Item 3.02 concerns the conversion of convertible promissory notes into common stock. Between June 12–17, 2026, holders converted approximately $663,188 of debt into 2,444,447 shares of common stock issued without Rule 144 restrictive legends. This represents a material dilutive issuance of equity securities that would affect a reasonable investor's assessment of ownership and capital structure, even though the conversions were pursuant to previously disclosed securities purchase agreements from 2025.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-18
Item 1.01
TransparentBusiness entered into material swap agreements on June 15 and 17, 2026 to acquire real-estate assets with an aggregate estimated value of $757.8 million in exchange for 4.24 billion Unicoin tokens. This constitutes a material acquisition of assets under Item 1.01, with the company issuing a substantial number of tokens (a form of equity consideration) to acquire significant real property holdings in the Philippines and Papua New Guinea.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-18
EX-99.1
This press release announces the establishment of in vitro proof-of-concept data for VERAXA's novel BiTAC-ADC technology platform and the company's intention to launch partnering discussions at BIO International Convention 2026. The disclosure is primarily operational and strategic in nature—it describes a technology validation milestone and business development activity (partnering discussions) rather than a financial event, executive change, M&A transaction, or other specifically enumerated event type. The data validation and partnering initiative represent material operational progress for an emerging biotech company, affecting investor assessment of the company's pipeline and commercial prospects.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-18
Item 5.02
While the filing discloses both a director departure (Mario Manzo's resignation on June 13, 2026) and an appointment (Franco Cappelli appointed to fill the vacancy and serve as chairman), the principal action emphasized is Cappelli's appointment to provide "continuity and support the Company's ongoing efforts to satisfy its SEC reporting obligations and execute its growth strategy." The Board's rationale centers on Cappelli's appointment as the solution to governance and operational challenges, making the appointment the salient event, though the departure is also material given Manzo's cited concerns about reporting status and governance deficiencies.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear disclosure of shareholder vote results from the June 17, 2026 annual meeting of stockholders. The filing reports voting outcomes for two proposals: the election of Ali Kashani and Touraj Parang as Class III directors, and the ratification of PwC as independent auditor. Item 5.07 is the designated 8-K item for shareholder vote results, and the prose explicitly presents vote tallies (votes for, against, abstaining, and broker non-votes) for each proposal.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-18
Item 1.01
Nuvve entered into a $1.5 million term loan agreement with ACH Capital West, LLC on June 12, 2026, with total repayment of $2.085 million due May 11, 2027, featuring aggressive weekly payments, substantial interest burden, and punitive default provisions that signal financial stress.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear disclosure of shareholder voting results from OmniAb's 2026 Annual Meeting held on June 17, 2026, filed under Item 5.07. The filing reports final voting tallies for two proposals: election of two Class I directors (Jennifer Cochran and Matthew W. Foehr) and ratification of Ernst & Young LLP as independent auditor. Both proposals passed with substantial majorities. This is a material event as it reflects shareholder approval of board composition and auditor selection.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear disclosure of shareholder voting results from Nuvalent's June 16, 2026 Annual Meeting of Stockholders, covering three proposals: election of Class II directors (Michael L. Meyers and Ron Squarer), advisory approval of named executive officer compensation, and ratification of KPMG LLP as independent auditor. The filing presents vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the standard format for Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This Item 5.07 disclosure reports the results of Douglas Elliman's 2026 annual meeting of stockholders held on June 18, 2026, including voting outcomes for three proposals: election of directors (Michael S. Liebowitz and Mark D. Zeitchick), ratification of EisnerAmper LLP as independent auditor, and an advisory say-on-pay vote. The tabulated vote counts and broker non-vote treatment directly match the shareholder_vote_results event type.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-18
Item 7.01
D-Wave announced a significant new product—its first gate-model quantum computing simulator with error-aware programming capabilities—along with new quantum development bundles launching in September 2026. This represents a material product milestone in the company's gate-model roadmap and introduces a new revenue-generating offering. While the disclosure does not fit neatly into the standard 8-K event categories (it is neither an earnings release, M&A activity, executive change, nor a financial restatement), the announcement of a differentiated, first-of-its-kind product with scheduled commercial availability and bundled pricing is material to investors assessing D-Wave's competitive position and near-term growth prospects.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
Blue Owl Real Estate Net Lease Trust sold 4,023,007 shares of Class I common shares for approximately $43.0 million in an unregistered offering exempt under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 8.01
The Company disclosed monthly NAV per share as of May 31, 2026 for all share classes (Class S: $10.6218, Class N: $10.7109, Class D: $10.4819, Class I: $10.6982), along with a detailed breakdown of NAV components totaling $9.3 billion, portfolio update, and share repurchase activity of $143.8 million.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
SharkNinja held its 2026 Annual General Meeting on June 18, 2026, with shareholders voting on and approving five matters: director re-appointments, auditor ratification, say-on-pay advisory vote, frequency of future say-on-pay votes, and amendment to the company's articles of association. All items were approved by shareholders with strong majorities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear disclosure of shareholder voting results from Burke & Herbert's Annual Meeting held on June 18, 2026, covering four proposals: election of 14 directors, ratification of Crowe LLP as auditor, advisory vote on executive compensation, and frequency of future advisory votes. The detailed voting tallies for each proposal and director are presented in tabular form, which is the standard format for Item 5.07 disclosures. This is material to investors as it confirms governance outcomes and shareholder sentiment on key matters.
View raw filing on EDGAR →
6-K
M&A activity
confidence 85%
filed 2026-06-18
The filing announces a High Court hearing scheduled for June 26, 2026, to sanction a scheme of arrangement relating to the proposed redomiciliation of Marex Group plc from the United Kingdom to Bermuda, with an expected effective date of July 1, 2026. A redomiciliation constitutes a material change of control or reorganization that would affect the registrant's corporate domicile, shareholder rights, and tax treatment—a transformative corporate event that would materially affect a reasonable investor's assessment of the company.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from Innventure's June 17, 2026 Annual Meeting of Stockholders. The filing reports final voting tallies for two proposals: election of three Class II directors (Bruce Brown, John Hewitt, and Catriona Fallon) and ratification of Withum Smith+Brown, P.C. as independent auditor. All three director nominees were elected with substantial majorities, and the auditor ratification passed overwhelmingly. This is material as it documents the outcome of the company's annual governance elections.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
Blue Owl Digital Infrastructure Trust sold 3,203,718 common shares across multiple classes for approximately $33.2 million in gross proceeds on June 1, 2026, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions from registration under the Securities Act of 1933.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 8.01
The filing discloses routine operational and financial metrics for the REIT as of May 31, 2026, including declared distributions per share class, NAV calculations, share repurchases, and portfolio composition.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
American Express issued €750 million of senior notes on June 17, 2026, a material debt issuance that affects the company's capital structure and financial obligations. While this is a routine debt offering disclosed under Item 8.01, it does not fit neatly into the more specific event categories (it is not M&A, not a covenant breach, not a restatement, etc.), making "other_material" the most appropriate classification for a significant financing event.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-17
Item 5.02
Daniel L. Poland, Executive Vice President and Chief Enterprise Transformation Officer, is stepping down from his current role effective August 3, 2026, with a transition period extending to January 10, 2027. This is a clear executive departure of a named officer at the C-suite level, making it material to investors assessing the company's leadership and operational continuity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-17
Item 5.02
The Board of Directors elected Brent McRae as President on June 15, 2026. This is a clear appointment of an officer to a principal executive role. The disclosure focuses on the election/appointment action and McRae's relevant background in cooperative governance, making this an executive appointment event material to investors assessing leadership changes.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 1.01
Potomac Electric Power Company entered into a Bond Purchase Agreement on March 19, 2026, and issued $300 million in aggregate principal amount of First Mortgage Bonds across three series (5.00%, 5.30%, and 5.74%) on June 17, 2026. This material debt financing transaction affects the registrant's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-17
Item 5.02
Lori Niederst was promoted to Chief Personal Lines Officer and Heather Day was appointed as CRM President, both effective July 4, 2026, as part of the Company's succession planning and executive reorganization.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-17
Item 7.01
The Company disclosed financial results for the month and year-to-date periods ended May 31, 2026, via a news release furnished under Regulation FD.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-17
Item 5.02
The Board elected Jill Livesay as a non-employee director effective July 1, 2026, and appointed her to the Audit Committee, expanding the Board from eight to nine members.
View raw filing on EDGAR →